Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis
- 29 January 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 19 (2), 82-90.e9
- https://doi.org/10.1016/j.clcc.2019.10.001
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Ephrin-A1 Is Up-Regulated by Hypoxia in Cancer Cells and Promotes Angiogenesis of HUVECs through a Coordinated Cross-Talk with eNOSPLOS ONE, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorialBMC Medical Research Methodology, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Cetuximab for the Treatment of Colorectal CancerThe New England Journal of Medicine, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Assessing Evidence Inconsistency in Mixed Treatment ComparisonsJournal of the American Statistical Association, 2006
- Bayesian random effects meta‐analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scalesStatistics in Medicine, 2002